Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial, The Lancet, vol.358, issue.9286, pp.958-965, 2001. ,
DOI : 10.1016/S0140-6736(01)06102-5
Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus Editorial pm ce infection: role of membrane oxidative damage, Hepatology, vol.5, issue.31, pp.58997-1004, 2000. ,
Adherence to combination therapy enhances sustained response in genotype-1???infected patients with chronic hepatitis C, Gastroenterology, vol.123, issue.4, pp.1061-1069, 2002. ,
DOI : 10.1053/gast.2002.35950
Population Pharmacokinetic and Pharmacodynamic Analysis of Ribavirin in Patients With Chronic Hepatitis C, Therapeutic Drug Monitoring, vol.22, issue.5, pp.555-565, 2000. ,
DOI : 10.1097/00007691-200010000-00010
Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection, New England Journal of Medicine, vol.361, issue.6, pp.580-593, 2009. ,
DOI : 10.1056/NEJMoa0808010
Hepatitis C Virus Treatment-Related Anemia Is Associated With Higher Sustained Virologic Response Rate, Gastroenterology, vol.139, issue.5, pp.1602-1611, 2010. ,
DOI : 10.1053/j.gastro.2010.07.059
Role of epoetin alfa in maintaining ribavirin dose, Gastroenterology Clinics of North America, vol.33, issue.1, pp.25-35, 2004. ,
DOI : 10.1016/j.gtc.2003.12.002
Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa, Am J Gastroenterol, vol.98, pp.2491-2499, 2003. ,
Replication of hepatitis C virus, Nature Reviews Microbiology, vol.281, issue.6, pp.453-463, 2007. ,
DOI : 10.1038/nrmicro1645
URL : https://hal.archives-ouvertes.fr/hal-00313684
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection, New England Journal of Medicine, vol.364, issue.25, pp.2405-2416, 2011. ,
DOI : 10.1056/NEJMoa1012912
Boceprevir for Untreated Chronic HCV Genotype 1 Infection, New England Journal of Medicine, vol.364, issue.13, pp.1195-1206, 2011. ,
DOI : 10.1056/NEJMoa1010494
Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection, New England Journal of Medicine, vol.364, issue.13, pp.1207-1217, 2011. ,
DOI : 10.1056/NEJMoa1009482
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3153125
Telaprevir for Retreatment of HCV Infection, New England Journal of Medicine, vol.364, issue.25, pp.2417-2428, 2011. ,
DOI : 10.1056/NEJMoa1013086
Clinical management of drug???drug interactions in HCV therapy: Challenges and solutions, Journal of Hepatology, vol.58, issue.4, pp.792-800, 2012. ,
DOI : 10.1016/j.jhep.2012.10.027
Dermatological side effects of hepatitis C and its treatment: Patient management in the era of direct-acting antivirals, Journal of Hepatology, vol.56, issue.2, pp.455-463, 2012. ,
DOI : 10.1016/j.jhep.2011.08.006
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) ??? NCT01514890, Journal of Hepatology, vol.59, issue.3, pp.434-441, 2013. ,
DOI : 10.1016/j.jhep.2013.04.035
477 ANEMIA HAD NO EFFECT ON EFFICACY OUTCOMES IN TREATMENT-NAIVE PATIENTS WHO RECEIVED TELAPREVIR-BASED REGIMEN IN THE ADVANCE AND ILLUMINATE PHASE 3 STUDIES, Journal of Hepatology, vol.54, p.195, 2011. ,
DOI : 10.1016/S0168-8278(11)60479-0
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic HCV genotype 1 infection?a randomized trial, Gastroenterology, vol.XX, p.XXX?XXX, 2013. ,
Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver, Liver International, vol.56, issue.17, pp.1477-1492, 2012. ,
DOI : 10.1111/j.1478-3231.2012.02856.x
Albert for his help in the preparation of the manuscript Conflicts of interest S. Pol has received consulting and lecturing fees from Bristol-Myers Squibb, p.0 ,